Based on promising preclinical results, Mithra Pharmaceuticals received orphan drug designation (a special status for drugs targeted to treat rare conditions) from the European Medicines Agency for estetrol (E4) as a treatment for neonatal encephalopathy (NE). Estetrol is an estrogen steroid hormone produced by the fetal liver during pregnancy that Mithra intends to develop to treat Hypoxic Ischemic Encephalopathy (HIE), a subset of NE. A preclinical study conducted in collaboration with the University of Liège (Belgium) indicated improvements in pathophysiology, general well-being and motor function. Mithra intends to investigate the potential neuroprotective properties of the drug in HIE, which could ultimately lead to clinical development of the drug as a treatment for HIE.
The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.
The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.